Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Inhaled GH001 in Healthy Subjects
NCT07540494Phase 1Completed
- Sponsor
- GH Research PLC
- Start
- Mar 2026
- Primary completion
- May 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mebufotenin in treatment-resistant depression (TRD), sponsored by GH Research PLC. Primary endpoints: Maximum observed concentration at Day 1, Time of maximum observed concentration at Day 1 and 9 more. Started Mar 2026; status: completed.
02
Drugs
mebufotenin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT07540494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07540494.